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Many metabolic pathways are critically regulated during develop-
ment and aging but little is known about the molecular mecha-
nisms underlying this regulation. One key metabolic cascade in
eukaryotes is the mevalonate pathway. It catalyzes the synthesis of
sterol and nonsterol isoprenoids, such as cholesterol and ubiqui-
none, as well as other metabolites. In humans, an age-dependent
decrease in ubiquinone levels and changes in cholesterol homeo-
stasis suggest that mevalonate pathway activity changes with age.
However, our knowledge of the mechanistic basis of these changes
remains rudimentary. We have identified a regulatory circuit con-
trolling the sumoylation state of Caenorhabditis elegans HMG-CoA
synthase (HMGS-1). This protein is the ortholog of human HMGCS1
enzyme, which mediates the first committed step of the mevalonate
pathway. In vivo, HMGS-1 undergoes an age-dependent sumoyla-
tion that is balanced by the activity of ULP-4 small ubiquitin-like
modifier protease. ULP-4 exhibits an age-regulated expression pat-
tern and a dynamic cytoplasm-to-mitochondria translocation. Thus,
spatiotemporal ULP-4 activity controls the HMGS-1 sumoylation
state in a mechanism that orchestrates mevalonate pathway acti-
vity with the age of the organism. To expand the HMGS-1 regula-
tory network, we combined proteomic analyses with knockout
studies and found that the HMGS-1 level is also governed by the
ubiquitin–proteasome pathway. We propose that these conserved
molecular circuits have evolved to govern the level of mevalonate
pathway flux during aging, a flux whose dysregulation is asso-
ciated with numerous age-dependent cardiovascular and cancer
pathologies.
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Many metabolic pathways are critically regulated during de-velopment and aging, but little is known about the molecular
mechanisms underlying this regulation. The mevalonate pathway is
a key metabolic cascade that converts acetyl-CoA and acetoacetyl-
CoA to farnesyl diphosphate, a precursor of sterol isoprenoids
such as cholesterol, steroid hormones, and bile acids. In addition,
farnesyl diphosphate feeds into cascades that synthesize nonsterol
isoprenoids, such as heme-A and ubiquinone, required for electron
transfer during respiration (1). Moreover, the mevalonate pathway
catalyzes the synthesis of essential intermediates for tRNA modi-
fication, protein glycosylation, and protein prenylation. Protein
prenylation is a requisite step in the activation of proteins involved
in many intracellular signaling pathways that control cell growth
and differentiation. For example, prenylation of small G proteins
from the Ras, Rho, and Rac superfamilies dictates the membrane
localization of these proteins that is essential for their activa-
tion (2). Although the main trunk of the pathway is conserved
in eukaryotes, some of the downstream branches vary between
organisms. In fungi the main structural sterol produced by the
pathway is ergosterol instead of cholesterol in vertebrates, whereas
in some invertebrates, including Caenorhabditis elegans, the sterol
synthesis branch is absent (3).
Many cellular processes and physiological states rely on vari-
able levels of mevalonate pathway metabolites, suggesting that
the pathway activity is highly regulated during the organism’s life
cycle. Elucidating the molecular details of this regulation is the
first step in understanding how pathway dysregulation leads to
diseases. For example, as part of the tumorigenic process of
breast cancer cells, the expression of many mevalonate pathway
enzymes is up-regulated by a mutant p53 protein (4). This
overactivation of the mevalonate pathway is both necessary and
sufficient to induce the mutant p53 phenotype in cancerous
breast tissue architecture. Studies of mevalonate pathway regu-
lation have primarily focused on regulators of HMG-CoA re-
ductase (HMGCR), which converts HMG-CoA into mevalonate
(5). HMGCR catalyzes the primary rate-limiting step of the
mevalonate pathway and is therefore highly regulated by tran-
scriptional and posttranscriptional control (6). The regulation of
other enzymes in the pathway is largely unexplored, but growing
evidence suggests that enzymes beyond HMGCR can serve as
flux-controlling points (7). One potential regulatory node is the
first committed enzyme of the pathway, HMG-CoA synthase
(HMGCS1). This cytoplasmic enzyme mediates the condensa-
tion of acetyl-CoA and acetoacetyl-CoA to HMG-CoA. hmgcs1
transcription is highly controlled by cholesterol levels in humans
(8). In addition, whole-proteome studies of posttranslational
modifications have identified specific HMGCS1 residues that
undergo phosphorylation (9), acetylation (10), and ubiquitina-
tion (11–13). These findings suggest that HMGCS1 undergoes
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complex posttranslational regulation, but the biological signifi-
cance of these modifications remains unclear.
Among the growing family of ubiquitin-like modifiers (UBLs),
ubiquitin and small ubiquitin-like modifier (SUMO) are the
most studied proteins. These two proteins share analogous en-
zymatic cascades that mediate, as a final step, covalent conju-
gation of the modifier to lysine residues of the substrate. In
contrast to the canonical role of ubiquitin as mediator of protein
degradation, conjugation of SUMO (sumoylation) can alter
protein activity, localization, and stability without directly caus-
ing degradation. SUMO has emerged as a critical regulator in
a variety of processes including cell cycle regulation, transcrip-
tion, nuclear architecture control, chromosome stability regula-
tion, and subcellular transport (14, 15). So far, the role of
sumoylation in metabolic control has been attributed primarily
to its transcriptional regulation activity, as in the regulation of
the metabolic transcription factor HIF-1a. However, SUMO is
also conjugated to the mitochondria fission protein DRP-1 (16),
and some metabolic enzymes have been identified among the
pool of potential SUMO targets (17). These findings suggest
that SUMO might play a direct role in metabolic regulation.
SUMO modification is a highly dynamic and reversible process
in part due to the activity of ubiquitin-like proteases (ULPs) and
sentrin-specific proteases (SENPs) that cleave SUMO from the
substrate (18). This highly conserved family of cysteine proteases
includes Ulp1 and Ulp2 of Saccharomyces cerevisiae; ULP-1,
ULP-2, ULP-4, and ULP-5 of C. elegans; and SENP1– SENP3
and SENP5–SENP7 of humans (18, 19). SUMO proteases share
the same domain organization of a conserved catalytic domain
close to the C-terminal end and a variable N-terminal domain
that dictates the protease subcellular localization and substrate
recognition. Studies in yeast and mammals have revealed that most
SENPs localize to the nucleus in recognizable subnuclear com-
partments (18). In recent years, however, emerging data have
demonstrated that some SENPs/ULPs also localize to the cyto-
plasm and intracellular organelle surfaces. For example, Ulp1
localizes primarily in the nuclear pore complex but translocates
to the cytoplasm in a cell cycle-specific manner (20). Even more
strikingly, SENP5 localization cycles between the nucleus and the
outer surface of the mitochondria. At the mitochondria, it regu-
lates organelle morphology by controlling the sumoylation state
of the mitochondria fission protein DRP-1 (21). Beyond these
few cases, the role of SENPs/ULPs in the regulation of cyto-
plasmic and mitochondrial processes has yet to be explored.
Here we describe a previously unidentified regulatory circuit
that orchestrates HMGS-1 levels with age. We found that HMGS-1
undergoes an age-dependent sumoylation that is temporally
balanced by the activity of ULP-4 SUMO protease. In addition
to a role for sumoylation, we discovered that the ubiquitin–
proteasome system also controls HMGS-1 levels. Evolutionary
conservation of both mechanisms suggests that this regulatory
network is fundamental to mevalonate pathway activity in
eukaryotes. Our findings place the first committed enzyme of the
pathway as a target for complex posttranslational regulation.
Results
ULP-4 SUMO Protease Exhibits Cytoplasm-to-Mitochondria Translocation.
As a first step in the study of SUMO proteases’ role in whole-
organism development, we have focused on the family of C. elegans
ULPs (Fig. S1). In the process of exploring the expression patterns
of these ULPs, we found that a GFP-labeled ULP-4 exhibits a
developmentally regulated expression pattern that is dependent
on tissue type and worm age (Fig. 1). Notably, ULP-4::GFP rescues
ulp-4 deletion mutant phenotypes (see ulp-4 Mutant Worms Are
Metabolically Impaired); furthermore, its GFP signal is reduced
by ulp-4 RNAi (Fig. S2). These suggest that the construct rep-
resents endogenous ULP-4 activity. ulp-4 expression initiates
in body wall muscles (BWMs) and hypodermal cells during
embryonic development (Fig. 1 A–C) and is maintained through-
out the worm’s life (Fig. 1 D–H). During the development from
larval stages 1–3, ulp-4 is expressed in the pharynx and hypodermis
(Fig. 2D). A second phase of ulp-4 expression in BWMs and
Fig. 1. ULP-4 exhibits a cytosol-to-mitochondria translocation. (A–C) ULP-4
expression initiates at midembryogenesis in muscles. ULP-4 protein is distrib-
uted in the cytoplasm. (D) ULP-4 protein cytoplasm-to-mitochondria trans-
location in hypodermal cells at L1 stage. Pharyngeal cells also start to express
ULP-4 that is sorted to the mitochondria. (E) At L3 BWM cells express ULP-4 as
a cytoplasmic protein (arrow). (F) At L4, ULP-4 expression initiates at the HSNs
concomitant with ULP-4 translocation to the mitochondria of head and tail
muscles. (G) Day-1 adult worms exhibit mitochondrial localization of ULP-4
in HSNs and most of the BWM cells. G, Inset shows a muscle anterior to the
HSN soma where ULP-4 is still cytoplasmic. (H) In day-10 adult worms, ULP-4
localizes to the mitochondria of all muscle cells. H, Inset shows mitochondrial
ULP-4 in the region as in G. (I–J″) Colocalization of ULP-4 with the mitochon-
drial outer membrane marker TOM-20::mRFP in muscles demonstrates ULP-4
matrix localization. (I) A merged image of a single muscle cell. (J–J″) A single
organelle analysis of TOM-20:mRFP distribution (J), ULP-4::GFP localization (J′),
and merged distributions (J″). (K ) A comprehensive diagram of ULP-4 ex-
pression and localization pattern. In all experiments, n ≥ 15 worms. (Scale
bars: 10 μm in A–C, 50 μm in D–H, 10 μm in G and H Insets, 10 μm in I, and
2.5 μm in J.)












hermaphroditic-specific neurons (HSNs) starts at L4 stage (Fig.
1F) and continues through adulthood (Fig. 1 G and H). Although
the ULP-4 localization pattern varies between tissue types, we
found a common pattern of subcellular localization with time. In
each tissue, ULP-4 protein initially localizes to the cell’s nucleus
and cytoplasm but accumulates later in development in in-
tracellular compartments that resemble mitochondria (Fig. 1K).
We confirmed the mitochondrial localization by colocalization
of ULP-4::GFP with TOM-20::mRFP, a protein that labels the
outer mitochondria membrane (Fig. 1 I and J). High-resolution
optical cross-sections through the organelle suggest that ULP-4
accumulates in the mitochondrial matrix. Likely, this age-regu-
lated subcellular localization determines ULP-4 substrate speci-
ficity by changing its site of action.
ULP-4 Interacts with C. elegans HMGS-1. Identification of substrates
is crucial for understanding the role of SENPs/ULPs in cellular
processes. Intrigued by the ULP-4 localization pattern, we
screened C. elegans two-hybrid libraries to identify potential
substrates. Because the N-terminal portion of many SENPs/
ULPs has been identified as the substrate recognition domain
(22), we used different regions of this domain as bait (Fig. 2A).
The screen revealed eight independent interaction events be-
tween ULP-4 and the HMGS-1 protein (Fig. 2A). C. elegans
HMGS-1 is the ortholog of two metabolic enzymes of mam-
mals: HMGCS1 and HMGCS2. HMGCS1 is the first commit-
ted enzyme of the mevalonate pathway (3), whereas HMGCS2
functions in ketone body synthesis (23). Reports about ketone
body metabolism in invertebrates are scarce (24, 25), so we
focused on whether HMGS-1 is required for mevalonate
pathway metabolism. hmgs-1 RNAi induces strong and robust
phenotypes including paralysis, reduced pharyngeal pumping,
and sterility (Fig. S3B and Movie S1). In agreement with pre-
vious reports on the involvement of hmgs-1 in the mevalonate
pathway (26, 27), these hmgs-1 RNAi phenotypes were fully
rescued by mevalonate supplementation, indicating that C. elegans
HMGS-1 is functionally equivalent to its ortholog HMGCS1 (Fig.
S3B and Movie S2).
HMGS-1 Is Sumoylated in Vitro at Lys408. The interaction between
ULP-4 SUMO protease and HMGS-1 suggests that HMGS-1 is
sumoylated. To understand the molecular details of HMGS-1
Fig. 2. HMGS-1 is sumoylated in an age-dependent manner in vivo. (A) ULP-4 and HMGS-1 protein fragments interact in a yeast two-hybrid assay. (B–D) In
vitro sumoylation reactions. Lanes labeled with −E2 are control reactions in which UBC9 is absent and −S are controls in which substrate is absent. (B) Time
course (in minutes) of HMGS-1 sumoylation. (C) Similar to HMGS-1, human HMGCS1 is sumoylated in vitro. (D) The sumoylation pattern of WT and various
lysine-to-arginine HMGS-1 mutants constructed based on sumoylation prediction (Fig. S4A). 4KR is a HMGS-1 variant whose four predicted sumoylated lysines
were mutated to arginines. Arrows mark the sumoylated-HMGS-1 bands, and asterisks label sumoylation-abolished HMGS-1 variants. (E) An assay for HMGS-1
sumoylation detection in vivo. IB, immunoblot. (F) HMGS-1 sumoylation increases with age and temperature until day 10 of adulthood. Total levels of HMGS-1
were determined by HMGS-1::FLAG::GFP detection from the total lysates. (G) ULP-4 knockdown resulted in increased HMGS-1 sumoylation whereas ULP-4
overexpression (ulp-4 OEx) resulted in a mild decrease of HMGS-1 sumoylation.
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modification, we first tested whether HMGS-1 is sumoylated
in vitro. We found that a recombinant, bacterial-expressed
C. elegans HMGS-1 protein is efficiently sumoylated in vitro
when incubated with human SUMO-1, E1, UBC9, and ATP
(Fig. 2B). To examine a possible evolutionary conservation of
this mechanism, we used the same in vitro sumoylation assay
on recombinant human HMGCS1 and found that it is also
sumoylated. This observation suggests that this mode of regu-
lation is evolutionarily conserved in humans (Fig. 2C). To
identify the sumoylated residue, we surveyed the HMGS-1
protein sequence for predicted sumoylation sites. Of the 27
HMGS-1 lysines, sumoylation site prediction programs identi-
fied four potential sites (Fig. S4A). In agreement with this pre-
diction, the HMGS-1 sumoylation level was reduced when we
mutated all four predicted lysines to arginines (Fig. 2D). Single
Lys-to-Arg mutations pinpointed the sumoylated residue as
Lys408. Lys408 is a strong candidate to be the site of HMGS-1
sumoylation in vivo as it has the highest sumoylation prediction
score and is sumoylated in vitro. Moreover, this residue is con-
served in the mammalian HMGCS1 sequence, and undergoes
ubiquitination (12) (Figs. S4B and S5). This conservation may
represent an evolutionarily conserved cross-talk between
sumoylation and ubiquitination. Sumoylation of Lys408 might
protect the protein from ubiquitination that occurs at the same
site (28), or it might elicit sumoylation-dependent ubiquitination
(e.g., ref. 29).
In Vivo, HMGS-1 Is Sumoylated in an Age-Dependent Manner. To test
whether C. elegans HMGS-1 is sumoylated in vivo, we immu-
noprecipitated a GFP-3×FLAG-tagged version of HMGS-1 and
assessed its sumoylation state by anti-SUMO antibodies (Fig.
2E). We found that HMGS-1 is sumoylated when the cultures
include worms grown for at least 4 d as gravid adults (Fig. 2F).
The size shift of the modified HMGS-1 is about 20 kDa, corre-
sponding to monosumoylation. The fact that HMGS-1 sumoy-
lation was detected only in cultures with worms older than day-4
gravid adult suggests that HMGS-1 is being sumoylated in an
age-dependent manner. To test the dynamics of HMGS-1 SUMO
conjugation, we grew synchronized, sterile cultures of worms and
examined the degree of HMGS-1 sumoylation in 5-d intervals
during adulthood. Strikingly, we found that the level of HMGS-1
sumoylation increases with age from day 1 of adulthood (no de-
tectable sumoylation) until day 10 (maximum sumoylation; Fig.
2F). To test the possible effect of environmental conditions on
HMGS-1 modification, we repeated the analysis on synchronized
cultures grown at 25 °C, a mild stress condition. We found the
same pattern of age-dependent HMGS-1 modification; however,
the level of HMGS-1 sumoylation increased relative to worms of
the same age grown at 20 °C. This suggests that environmental
factors that change the physiological state of the organism can also
change the level of HMGS-1 modification. Worms fed with smo-1
RNAi exhibited an almost complete elimination of the SUMO
band, demonstrating the specificity of this assay (Fig. 2G). To
study the effect of ULP-4 activity on the HMGS-1 modification
state, we knocked down ULP-4 SUMO protease by RNAi. Strik-
ingly, this knockdown resulted in an increased level of HMGS-1
sumoylation in vivo (Fig. 2G). This finding accords with both the
interaction between HMGS-1 and ULP-4 found in the two-hybrid
screen and the proposed enzymatic activity of ULP-4 as a SUMO
protease. Taken together, these results reveal a previously un-
identified molecular circuit in which controlled activity of ULP-4
SUMO protease balances the level of HMGS-1 sumoylation.
ulp-4 Mutant Worms Are Metabolically Impaired. To unveil the
function of ULP-4 SUMO protease, we characterized the phe-
notypes resulting from a deletion in the ulp-4 locus. This allele
introduces a frame shift followed by a stop codon at the begin-
ning of exon 4 (Fig. S6), presumably resulting in a severe de-
crease of ULP-4 function. Worms homozygous for this allele are
viable but exhibit phenotypes associated with impaired metabo-
lism. ulp-4 mutants are almost completely sterile; furthermore,
their pumping rate and locomotion undergo a notable decline
with age (Fig. 3A). In addition, ulp-4 mutants have significantly
less fat (Fig. S6C). This effect can be partially rescued by the
ULP-4::GFP construct, demonstrating that these phenotypes
stem from ULP-4 loss. Remarkably, these phenotypes show
a strong age dependency consistent with ulp-4 age-dependent
expression as well as with the proposed role of ULP-4 as a regu-
lator of the mevalonate pathway. Consistent with this observation,
ulp-4 mutant worms are long-lived, whereas ULP-4::GFP worms,
in which ULP-4 is mildly overexpressed, are short-lived (Fig. S7).
Through ubiquinone and heme-A synthesis, mevalonate path-
way flux is directly required for proper electron transport (Fig.
S3A). To examine the possible effect of ulp-4 loss on mitochondria
homeostasis, we measured the degree of mitochondria membrane
potential and respiration. ulp-4 mutant mitochondria fail to
maintain normal membrane potential as determined by tet-
ramethylrhodamine ethyl ester (TMRE) staining (Fig. 3D). In
addition, ulp-4 loss results in decreased oxygen consumption
relative to WT worms (Fig. 3E), whereas ULP-4::GFP worms
consume more oxygen than WT worms. Dysregulation of the
mevalonate pathway likely impairs mitochondrial electron
transport rate by affecting coenzyme Q production, thereby
affecting lifespan and the rate of respiration (30). Although
ULP-4 probably has many targets, it is possible that the ulp-4
mutant phenotypes described above stem, at least in part,
from dysregulated HMGS-1 activity. To examine this hy-
pothesis, we tried to rescue the ulp-4 loss of function pheno-
types by adding mevalonate exogenously. Indeed, mevalonate
supplementation rescues ulp-4 mutants’ reduction of pumping
in a dosage-dependent manner, whereas only marginally affecting
the pumping rates of WT worms (Fig. 3C). Taken together, these
results show the role ULP-4 plays in controlling the mevalonate
pathway and worm metabolism. A partial rescue of ulp-4 mutant
phenotypes by mevalonate demonstrates that oversumoylated
HMGS-1 is less active, placing ULP-4 as a positive regulator
of HMGS-1 activity. This uncovers the mechanistic basis by
which HMGS-1 sumoylation and ULP-4–mediated desumoylation
control the mevalonate pathway.
HMGS-1 Interacts with the Ubiquitin–Proteasome Pathway. To
characterize the molecular circuits that control HMGS-1 more
comprehensively, we searched for HMGS-1 interactors by im-
munoprecipitation (IP), followed by mass spectrometry (MS)
analysis. We identified 663 proteins that were enriched in an
HMGS-1–immunoprecipitated fraction in comparison with the
control (Dataset S1). The list of HMGS-1 interactors was enriched
in five Kyoto Encyclopedia of Genes and Genomes (KEGG, www.
genome.jp/kegg) pathways (Fig. 4A and Fig. S8). Three of these
(valine/leucine/isoleucine degradation, citrate cycle, and propanoate
metabolism) feed substrates into the mevalonate pathway (acetyl-
CoA or acetoacetyl-CoA, explicitly) that are metabolized by
HMGS-1. This raises the possibility that HMGS-1 functions as part
of a high-order metabolic scaffold (Fig. 4A). A fifth enriched
pathway is ubiquitin–proteasome, which may lead to degradation of
HMGS-1. Strikingly, 20 proteins that coprecipitated with HMGS-1
are in the broader ubiquitin–proteasome pathway (Fig. S8). These
include an E2 ubiquitin carrier (UBC-13), an ubiquitin fusion
degradation enzyme (UFD-1), a proteasomal ubiquitin adaptor
(ADRM-1–like) (31), and an ubiquitin carboxyl-terminal hydrolase
UBH-4. To test the potential role of HMGS-1 ubiquitination, these
interactors were knocked down by RNAi. Knockdown of either
UBA-5 or UBC-13 interactors resulted in an increased HMGS-1::
GFP signal in comparison with an empty vector control (Fig. 4B).
This demonstrates a role of the ubiquitin pathway in HMGS-1
regulation. To examine whether the identified HMGS-1 regulatory












network is conserved in sterol-producing organisms, we searched
the protein–protein interaction database Biological General
Repository for Interaction Datasets (http://thebiogrid.org) (32).
Consistent with our findings in C. elegans, the HMGS-1 ortholog
ERG13 of the sterol-producing yeast S. cerevisiae is suggested to
be both sumoylated (33) and ubiquitinated (34). ERG-13 inter-
acts with ubiquitin (UBI4), ubiquitin-specific protease (UBP3),
SUMO (SMT3), and a SUMO protease (ULP1) (35) (Fig. 4D),
as well as with various proteasomal subunits. So far, only a small
set of interactors have been identified for HMGCS1, the human
ortholog of HMGS-1. Although limited in number, the pool of
HMGCS1 interactors includes the polyubiquitin-C protein (11,
12). High throughput screens have suggested that human
HMGCS1 undergoes ubiquitination at multiple sites (Fig. S4),
but the outcome of this modification is not yet clear. This in-
teraction and our finding that HMGCS1 is sumoylated in vitro
suggest that this regulatory circuit is also conserved in humans.
A Model for the HMGS-1 Regulatory Circuit. Collectively, the mol-
ecular, genetic, and metabolic data suggest a model in which
HMGS-1 activity is governed by two modes of posttranslational
modification (Fig. 4C). We propose that the balance between
HMGS-1 sumoylation and desumoylation is highly regulated
during the lifespan of the organism and is used to control the
level of HMGS-1 activity. This balance orchestrates HMGS-1
activity with respect to tissue type, developmental stage, and
the organism’s age. Early in the development of C. elegans, the
activity of ULP-4 in the cytoplasm results in less sumoylated
and presumably more active HMGS-1. As the worm ages,
mitochondrial sequestration of ULP-4 results in HMGS-1
oversumoylation and inactivation (Fig. 4D). In addition, the
ubiquitin–proteasome pathway also governs HMGS-1 levels,
highlighting how critical control of HMGS-1 levels is. It is
possible that a cross-talk between sumoylation and ubiquiti-
nation dictates HMGS-1 levels or that these two pathways are
acting as two parallel branches within the HMGS-1 regula-
tory network. Nevertheless, these regulatory circuits not only
explain how spatial and temporal control of mevalonate
pathway flux evolved, they also place HMGS-1/HMGCS1 as
a target for age-dependent posttranslational regulation. In
addition to the dynamic control of HMGCR levels by ubiq-
uitination (36), HMGS-1/HMGCS1 posttranslational regula-
tion presumably plays a more long-term role in mevalonate
pathway control. One potential implication of our findings is
Fig. 3. ULP-4 loss results in age-dependent metabolic phenotypes. (A) Pharyngeal pumping rate is reduced in ulp-4(-)mutant worms relative to the pumping
rate of WT worms. (B) ulp-4(-) worms exhibit an accelerated age-dependent reduction of locomotion. (C) Nutritional supplementation of mevalonate rescues
the ulp-4(-) mutant phenotype. Worms were grown at 20 °C and tested at day 1 of adulthood. Error bars represent SEs. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001,
****P ≤ 0.0001. (D) Lack of TMRE accumulation demonstrates that mitochondria homeostasis is impaired in worms lacking ulp-4. (Scale bars: 20 μm) (E) ULP-4
activity is required for proper respiration. ulp-4(-) worms exhibit a significant reduction in oxygen consumption. This reduction was rescued by the ULP-4::GFP
construct described in Fig. 1.
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a mechanistic understanding of how the mevalonate pathway
flux is controlled with age. We hypothesize that in humans,
perturbations of this regulatory circuit may result in an age-
dependent overactivation of the mevalonate pathway that
leads to cholesterol overproduction and cancer progression.
Discussion
Despite their vital role in numerous cellular processes related to
health and disease, little is known about posttranslational mech-
anisms that control the mevalonate pathway beyond HMGCR.
We have applied genetic and proteomic screens along with de-
velopmental, metabolic, and biochemical approaches to discover
an evolutionarily conserved mechanism that controls HMGS-1
levels. This molecular circuit includes age-dependent HMGS-1
sumoylation that is balanced by the spatiotemporally regulated
activity of the ULP-4 SUMO protease. We also identified the
ubiquitin–proteasome pathway as part of the HMGS-1 regulatory
network and demonstrated its role in controlling HMGS-1 levels.
By identifying HMGS-1 as the target for both ubiquitination
and age-controlled sumoylation in vivo, we set the foundation
for a mechanistic understanding of HMGS-1 posttranslational
regulation within the context of the dynamic metabolism of
the organism.
Studies on sumoylation were carried out primarily in single-
cell systems such as yeast and mammalian cells in culture (19,
37). It is not clear how sumoylation is controlled in a whole or-
ganism with various tissue types and a complex life cycle. The
unexpectedly complex but stereotypic expression and subcellular
localization pattern of ULP-4 (Fig. 1) may serve as a mechanism
by which SUMO proteases temporally govern developmental
processes. In contrast to SENP5 that localizes at some stages of
the cell cycle on the mitochondria outer surface (21), our high-
resolution analyses show that ULP-4 translocates to the mito-
chondrial matrix (Fig. 1K). Although we cannot rule out the
possibility that ULP-4 deconjugates sumoylated mitochondrial
matrix proteins, our results suggest that localization to the mi-
tochondrial matrix sequesters ULP-4, preventing its cytoplasmic
function. The ULP-4 protein does not have a defined mito-
chondria-sorting signal, but it may harbor a noncanonical signal
as do more than 50% of the mitochondrially sorted proteins (38).
Consistent with reports on other SENPs/ULPs (20), substrate
recognition by ULP-4 was dependent on its N-terminal portion
(Fig. 2A). This region harbors a signature acidic stretch that also
exists in the N-terminal portion of human SENP3 and less evi-
dently in the ULP-4 orthologs SENP6/SENP7 (Fig. S9). This
acidic stretch may play a conserved role either in subcellular
sorting or in substrate recognition.
Our temporal biochemical analyses clearly show that HMGS-1
undergoes age-dependent sumoylation (Fig. 2) and that this
sumoylation is regulated by the activity of an age-controlled
protease (Figs. 1 and 2). Although sumoylation may be a pow-
erful mechanism to regulate protein activity with age, only a few
cases of regulated sumoylation have been reported. Global
sumoylation analyses comparing 3- and 25-mo-old mice spleens
revealed that a few uncharacterized proteins undergo age-
enhanced sumoylation in a SUMO-1 specific manner (39). In
addition, SUMO-3 conjugation is reported to play some role in
age-dependent learning and memory decay. In the AβPP Tg2576
mouse model of Alzheimer’s disease, SUMO-1 conjugation of
a yet-to-be identified substrate increased at 3 and 6 mo in
comparison with 1.5 mo of age (40). To our knowledge, age-
dependent sumoylation of HMGS-1 is the first reported case of
well-characterized, regulated sumoylation with age. Presumably,
age-dependent SUMO conjugation is a widespread mechanism
controlling many metabolic and signaling networks during aging.
In contrast to the still uncharacterized role sumoylation
plays during aging, the involvement of the ubiquitin–protea-
some pathways is well established (41, 42). In C. elegans for
example, proteasomal E3 ligase activity regulates lifespan
(43), and elevated levels of proteasomal protein RPN-6 me-
diate somatic lifespan extension (44). This demonstrates how
changes of the activity of the protein degradation machinery
may consequently affect the lifespan of the organism. By their
Fig. 4. HMGS-1 interaction network and a proposed regulatory circuit. (A)
HMGS-1 interactors, revealed by HMGS-1 IP and MS. Shown are KEGG path-
ways significantly enriched (see also Fig. S8A). The four enriched metabolic
pathways are involved in either acetyl-CoA or acetoacetyl-CoA metabolism
suggesting that HMGS-1 is part of high-order metabolic scaffolds. Twenty
proteins from the proteasome and ubiquitin pathway were also identified
(Fig. S8C). (B) Worms expressing HMGS-1::GFP were subjected to RNAi against
candidate genes corresponding to proteins identified as HMGS-1 interactors
from the proteomic screen. Depletion of UBA-5 and UBC-13 leads to an
elevated level of HMGS-1::GFP. (Scale bars: 200 μm) (C) A survey of protein–
protein databases demonstrated that HMGS-1 regulatory network is con-
served in sterol-producing organisms. UBL-Tag are either ubiquitin or SUMO
modifiers and UBL-proteases are either ubiquitin or SUMO proteases. (D) A
model for the HMGS-1 regulatory circuit. This model suggests that balance
between HMGS-1 sumoylation and desumoylation affects HMSG-1 activity
and mevalonate pathway flux. H, C. elegans HMGS-1; [Mev], mevalonate
pathway flux; Su, C. elegans SUMO; Ub, C. elegans ubiquitin-A.












nature, MS analyses (Fig. 4B and Fig. S8) are not tissue specific
and represent the sum of interactors in the whole organism. As
with ULP-4 (Fig. 1), it is likely that a spatiotemporal activity of
specific interactors dictates the level HMGS-1 ubiquitination
and activity in a tissue and age-specific manner. The cross-talk
between the ubiquitin–proteasome and SUMO pathways may
serve as a central mode of posttranslational modification. For
example, substrate sumoylation triggers ubiquitination and pro-
tein degradation via the activity of SUMO-targeted ubiquitin E3
ligases (e.g., ref. 45). Likewise, HMGS-1 sumoylation at old age
may lead to the binding of SUMO-dependent ubiquitin E3
ligases and protein degradation.
One fundamental characteristic of metabolism is its gross
dependency and effect on the organism’s life cycle. In many
cases, metabolism is modulated and even rewired as the organ-
ism develops, ages, and copes with environmental and physio-
logical stress. For example, an expression analysis of the
C. elegans stress-resistant dauer larvae identified a switch from
oxygenic respiration to anaerobic fermentation (46, 47). Even
within the same organism, different tissues exhibit gross vari-
ability in metabolic profile. A comparison among 10 human
tissues revealed that posttranscriptional regulation plays a cen-
tral role in shaping tissue-specific metabolic profiles (48). Due to
its vital role in cellular growth, differentiation, and basic activi-
ties such as cellular respiration, the mevalonate pathway is
probably highly regulated during the life cycle of the organism.
In humans, an age-dependent decrease in ubiquinone levels (49)
and changes in cholesterol homeostasis (50) suggest that the
pathway’s activity changes with age. The dynamic regulation of
HMGR1 by cholesterol and cholesterol-related metabolites
probably cannot account for the more long-term control re-
quired during the organism’s life cycle (36). Notably, large-scale
proteomic studies reveal that almost every enzyme in the
mevalonate pathway is subjected to ubiquitination (7). This
suggests that ubiquitin-dependent degradation by the pro-
teasome may play a role at many rate-limiting points of the
pathway. So far, however, only one modified enzyme, squa-
lene monooxygenase, has been investigated in detail (51, 52).
The fact that HMGS-1/HMGCS1 activity allows substrates to
enter the mevalonate pathway places its regulation as an ef-
fective control of flux from the pathway’s starting point.
Consistent with this notion, the level of HMGCS-1 tran-
scription is highly controlled by the sterol-responding tran-
scription factor SREBP (6) and by mutant p53 (4). Our
findings highlight a HMGS-1 posttranslational modification
network as an important regulatory mechanism for controlling
the mevalonate pathway in C. elegans. Conservation of this
network in the sterol-producing yeast S. cerevisiae (Fig. 4C) as
well as the sumoylation of human HMGCS1 in vitro (Fig. 2C)
suggests that this evolutionarily conserved mechanism may
play a similar role in humans. Based on these data, we hy-
pothesize that regulated HMGCS1 sumoylation along with
ubiquitin–proteasome degradation control HMGS-1 activity
with age. Perturbation of this regulatory network may con-
tribute to pathway overactivation in various diseases such as
p53-driven tumorigenesis and age-dependent loss of choles-
terol homeostasis. This conserved molecular circuit could serve
as a handle for targeting the mevalonate pathway in future
therapeutics.
Methods
Yeast Two-Hybrid Screen. Yeast two-hybrid screens were performed by
mating as previously described (53). Four distinct regions of ulp-4 were used
as bait: FL-ULP-4 (amino acids 1–382), N-ULP-4 (amino acids 1–110), Ex2-
3ULP-4 (amino acids 58–145), and C-ULP-4 (amino acids 111–382). To avoid
ULP-4-related toxicity, the predicted catalytic cysteine of the active site was
mutated to serine (C743S) in constructs that bore the ULP-4 catalytic domain.
To generate the Gal4-DB::ulp-4 bait clones, the corresponding regions of the
ulp-4 coding sequence were PCR amplified from cDNA synthesized from
mRNA of mixed-stage WT worms. A forward primer containing an AscI re-
striction site immediately upstream of the coding region was used with
a reverse primer containing a stop codon followed by a NotI restriction site
immediately downstream of the ulp-4 coding region. These sites were used
to clone each of the four fragments into the Gal4 DB vector pMB27,
a modified version of pPC97 (54), which encodes a flexible linker (GGGG)
upstream of the cloned ORF, and contains a polylinker that facilitates
cloning using AscI and NotI restriction enzymes. Each of the Gal4-DB::ulp-4
bait constructs were transformed into yeast strain Y8800 (55) and mated to
a Gal4-AD-cDNA library (a generous gift from X. Xin and C. Boone, University
of Toronto, Toronto) and a Gal4-AD-Fragment library containing fragments
of 749 genes required for C. elegans early embryonic development (53). Both
libraries were in yeast strain Y8930 (55). Candidate interactors were selected
on Sc–Leu–Trp–His plates, and assayed on three additional plates: Sc–Leu–
Trp–His + 2 mM 3-amino-1,2,4-triazole to gauge the strength of activation of
the HIS3 reporter gene, Sc–Leu–Trp–Ade to gauge the strength of activation
of the ADE2 reporter gene, and Sc–Leu–His + 1 μg/mL cycloheximide to
identify yeast clones that are able to activate the HIS3 reporter gene in the
absence of an AD fusion protein as described (56). Clones that activate the
HIS3 reporter in the absence of a Gal4-AD interaction partner were elimi-
nated. The identity of the remaining interactors was determined by PCR
amplification from yeast cells and sequencing. As a final confirmation, we
isolated the Gal4-AD plasmids, and transformed them into fresh Y8930 cells,
which were mated with Gal4-DB-ULP-4 expressing Y8800 cells and again
assayed for activation of the HIS3 and ADE2 reporter genes. Eight in-
dependent HMGS-1 clones were isolated from the Gal4-AD-cDNA library.
Detection of in Vivo Sumoylation. Worms were washed from starved plates
and transferred to growing media (M9, 5 μg/mL cholesterol, 1 mM MgSO4,
and HB101 bacteria) and grown in liquid culture in one to three worms per
μL density at 20 °C or 25 °C. For synchronized cultures beyond 3 d of
adulthood, the fer-15(b26)II;fem-1(hc17)IV background was used. In this
background, worms were grown at 25 °C until day 1 of adulthood and then
were transferred to the desired temperature. Worms were harvested by
three to four cycles of M9 washing and collection by spinning 1,160 × g for
2 min. When the M9 became clear, worms were divided into microcentrifuge
tubes in aliquots of 300 mg compact worms. These aliquots were flash-fro-
zen in liquid nitrogen and stored at −80 °C until analyzed. From this point
forward, all steps were carried out at 4 °C unless otherwise stated. Worm
pellets were resuspended in two volumes of cold worm lysis buffer (50 mM
Tris·HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM PMSF,
200 μM iodoacetamide, 1 minitablet of Roche protease inhibitor–EDTA/10
mL buffer, and 25 mM N-ethylmaleimide) prepared fresh and added to every
tube just before sonication. Immediately after resuspension, worms were
sonicated in five 10-s intervals with 50 s between each sonication interval.
After sonication, each lysate was spun twice at 16,000 × g for 30 min and
finally 16,000 × g for 5 min, transferring the supernatant to a new tube each
time. After determination of protein concentration, 7 mg total protein from
each lysate was diluted in 800 μL lysis buffer. For the IP, FLAG beads (Sigma;
A2220) were thawed on ice, and 20 μL compact beads were used for every
300 μL compact worms. Lysate was placed on a roller overnight; then beads
were pelleted by centrifugation at 685 × g and washed three times in lysis
buffer. Next, protein was eluted from the beads by adding 100 μL 150 ng/μL
3×FLAG elution peptide in FLAG washing buffer. Samples were incubated
for 30 min before the supernatants were transferred to a new micro-
centrifuge tube and 900 μL RIPA added to each tube. Anti-GFP antibody
(Roche) was added to the tubes before incubating for 1 h. Next, protein-G
beads were added and tubes were gently rolled for 7 h at 4 °C. As a final
step, the beads were washed three times in FLAG washing buffer and
sample buffer was added directly to the bead pellet.
Sumoylation Prediction and in Vitro Sumoylation Assays. Potential sumoyla-
tion sites were identified by integrating the predictions of three sumoylation
prediction programs: SUMOplot (57), SUMOsp2.0 (58), and SUMO-RF. Lysine-
to-arginine mutagenesis of candidate sites was done using Agilent tech-
nologies Quick Change site Directed Mutagenesis kit. WT and mutant
HMGS-1 proteins were cloned into pET28B and transformed into BL-21
(DE3). Colonies were grown over 1 d at 37 °C, and protein expression was
induced by 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) overnight at
20 °C. Proteins were purified using standard techniques and were subjected
to buffer exchange using Amicon centrifugal filters MWCO 10 kDa. After
protein determination, 8 ng protein were used per sumoylation reaction
preformed according to the manufacture’s protocol. In vitro sumoylation
reactions took place at 37 °C with an optimal incubation time of 30 min.
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MS Analyses. IP. Worms were lysed in lysis buffer (1% Triton, 50 mM Tris pH
7.4, 150 mL NaCl, 1 mM EDTA, 250 μM iodoacetamide, 25 mM N-ethyl-
maleimide, 1 mM PMSF, 10 μM bortezomib, and 1 tablet of Roche complete
protease inhibitor) by sonication using parameters similar to the in vivo
sumoylation assays. Cell lysates were cleared by centrifugation for 30 min at
25,000 × g in an Eppendorf centrifuge (5417R), and supernatants were
transferred to a new tube to repeat the centrifugation. For each IP, 50 μL
FLAG beads were washed twice with 1 mL lysis buffer. Clear cell lysate was
incubated with FLAG beads at 4 °C for 1 h. Beads were washed with 1 mL
lysis buffer three times and 100 mM Tris buffer (pH 8.5) twice. Proteins were
eluted with 10 M urea in 100 mM Tris buffer (pH 8.5) by incubating at 37 °C
for 15 min.
In-solution tryptic digest followed by nano-liquid chromatography–tandem mass
spectrometry analysis. Eluted proteins (100 μL) were diluted with 25 μL 100
mM Tris buffer (pH 8.5), reduced with 1 μL 0.5 M tris (2-carboxyethyl)
phosphine hydrochloride (Thermo Fisher Scientific) for 20 min at 37 °C,
alkylated with 3 μL 0.5 M chloroacetamide (Fisher) for 15 min at 37 °C, and
digested with 2 μL 100 ng/μL Lysyl endopeptidase (Wako Chemicals; Lys-C)
for 4 h at 37 °C. Samples were diluted to a final concentration of 2 M urea by
adding 375 μL 100 mM Tris·HCl pH 8.5 and digested with 3 μL 100 ng/μL
trypsin (Thermo Fisher Scientific) with 5 μL 100mM CaCl2 for 18 h at 37 °C.
After desalting with Pierce C18 Tip (Thermo Fisher Scientific), peptides were
eluted with 200 μL 75% (vol/vol) acetonitrile (CAN) 0.1% TFA. Solvent was
removed using a SpeedVac. Dried samples were acidified by 0.2% formic acid
and loaded onto an Easy Nano-LC Q-Exactive Orbitrap (Thermo Fisher Scientific).
Peptides were loaded onto to a trap column [PepMap 100 C18, 3 μm, 75 μm ×
2 cm, nanoViper (Thermo Fisher Scientific)] and separated with an Easy-Spray
column [PepMap C18, 3 μm 100 Å, 75 μm × 15 cm (Thermo Fisher Scientific,
ES800) with a 2–30% (vol/vol) gradient (A: 0.1% formic acid [FA] in water; B:
0.1% FA in 100% CAN)] at 300 nL/min for 60 min followed by 30% (vol/vol) B to
100% B for 5 min and incubated at 100% B for 10 min.
The Q-Exactive acquisition method was created in data-dependent mode
with one precursor scan in the Orbitrap, followed by fragmentation of the 15
most abundant peaks. Resolution of the precursor scan was set to 70,000,
automatic gain control target 3e6, maximum injection time 100 ms, scanning
from 350 to 2,000 m/z. The MS2 resolution was 17,500, the AGC target 5e4,
the isolation window was 2.0 m/z, the fixed first mass 100.0 m/z, the nor-
malized collision energy was 25, the underfill ratio was 0.1%, the charge
exclusion was unassigned 1, peptide match was preferred, the exclude iso-
tope option was on, and the dynamic exclusion was 30.0 s.
The peak list generating software used was Proteome Discoverer Software
1.4.1.14 (Thermo Fisher Scientific). The outline of the method used in the
spectrum selector mode of the Proteome Discoverer software were all set to
default settings to generate tandem MS spectra. The precursor charge state
(high/low), retention time, minimum peak count, and total intensity
threshold value were all set to default settings. The maximum and minimum
precursor mass settings were 5,000 and 350 Da, respectively. The C. elegans
Fasta file (canonical and isoform) was downloaded from UniProt
(www.uniprot.org).
The Sequest HT search parameters included in this study were two missed
cleavages allowed, fully tryptic peptides only, minimum peptide length of 6,
maximum peptide length of 144, fixed modification of carbamidomethyl
cysteine (+57.021 Da), dynamic modifications of oxidized methionine
(+15.995Da), and N-terminal acetylation (+42.011Da). The precursor ion
mass tolerance was 10 ppm and fragment mass tolerance was 0.05 Da. The
input data maximum delta was Cn 0.05. The decoy database search was
applied with strict false discovery rates (FDR) of 0.01 and relaxed FDR of 0.05,
where the validation was based on q value.
Alignment of protein sequences and structures. The European Bioinformatics
Institute (www.ebi.ac.uk) ClustalW multiple sequence alignment server
(www.ebi.ac.uk/Tools/msa/clustalw2) was used to align all protein sequences
with the default setting. Sequences were further annotated using Jalview
2.8 software (59). Human HMGCS1 modifications are based on data available
from PhosphoSitePlus (www.phosphosite.org/homeAction.do). The Phyre
server (60) was used for the search of proteins with an HMGS-1–related
structure in the Protein Data Bank (www.rcsb.org/pdb/home/home.do) using
default parameters. For the structural alignment of HMSG-1 and HMGCS1,
we used PyMOL 1.3 software [The PyMOL Molecular Graphics System,
Version 1.3 (Schrödinger); www.pymol.org].
Phylogenetic analysis of C. elegans ULPs and other Ulp/SENP family members.
Protein sequences of Ulp/SENP were obtained by psi-BLAST search using
National Center for Biotechnology Information Entrez nonredundant data-
base (www.ncbi.nlm.nih.gov/refseq) or directly from genome sequencing
projects. Two hundred fifty sequences from 75 organisms representing the 4
kingdoms of eukarya were aligned using multiple sequence comparison in
the Log-Expectation program (61). Bootstrapping and determination of test
estimate of maximum-likelihood tree topology were conducted with Rapid
bootstrapping algorithm from RaxML Version 8.0.9 under the GTR+I model
running on the CIPRES portal (62). Consensus tree images were generated
using FigTree (www.molecularevolution.org/software/phylogenetics/figtree),
and the tree images then manipulated using Adobe Photoshop software.
C. elegans genetics. Worm strains were cultured as in ref. 63. All integrated
strains were out-crossed at least four times before experiments. The
tm33688 ulp-4 deletion was out-crossed at least seven times.
The strains used in this study were as follows:
PS6355: ulp-4 (tm3688)/mIn1 [mIs14 dpy-10(e128)] II
PS6366: ulp-4 (tm3688)/mIn1 [mIs14 dpy-10(e128)] II; tvIs92 [ulp-4p::ulp-4::
GFP]
PS6709: ulp-4 (tm3688)/mIn1 [mIs14 dpy-10(e128)] II; syIs261 [HMGS-1::
GFP 1 ng/μL + pha-1 50 ng/μL + myo-2::mRFP 5 ng/μL]
CF152: fer-15(b26) II; fem-1(hc17) IV
NX349: fer-15(b26) II; fem-1(hc17) IV; syIa261 [HMGS-1::GFP 1 ng/μL + pha-1
50 ng/μL + myo-2::mRFP 5 ng/μL]; him-5(e1490) V
PS6309: syIs268 [myo-3p::TOM20::mRFP (50 μg/μL) + unc-119 (50 ng/μL)] V,
tvIs92[ulp-4p::ulp-4::gfp; rol-6]
NX92: tvIs92[ulp-4p::ulp-4::gfp; rol-6]
PS6332: tvIs92 [ulp-4p::ulp-4::gfp], ljEx446 [pclh-3::mcherry (75 ng/μL), pRF4
(75 ng/μL]
ulp-4 molecular analysis and constructs. The tm3668 deletion in the ulp-4 locus
was characterized by PCR of genomic DNA. For analysis of ulp-4 transcripts in
a tm3688 background, total mRNA was purified from tm3668 homozygotes,
heterozygotes, and WT worms. The mRNA was subjected to RT-PCR ampli-
fication with ulp-4 specific primers. To generate ulp-4 constructs, ulp-4 DNA
was amplified using DNA Expand Taq (Roche) or PfuUltra (Agilent Tech-
nologies), cloned into relevant plasmids, and sequenced. Injection, handling,
and characterization of transgenic strains were done according to standard
procedures.
HMGS-1/HMGCS1 constructs and worm strains. HMGS-1 cDNA was amplified
from an open-biosystem RNAi library and cloned into pET28B plasmid
for bacterial expression and in vitro sumoylation. The QuikChange site-
directed mutagenesis technique (Agilent Technologies) was used for hu-
man HMGCS1 mutagenesis. For HMGCS1 cloning, total mRNA from human
GM12878 cells (pre–B-cell lymphoblastoid) was amplified with hmgcs1-
specific primers and cloned to the pET28B plasmid. To follow the ex-
pression pattern and sumoylation state of HMGS-1, worms were injected
with a fosmid that harbors a tagged version of HMSG-1. This fosmid,
which was obtained from the TransgeneOme project, had HMGS-1 fol-
lowed by 2×TY, GFP, and 3×FLAG tags. The GFP tag was used for expression
analysis, whereas the GFP and FLAG tags were used for biochemical anal-
yses. Because of toxicity, the fosmid was injected at a final concentration of
1 ng/μL.
RNAi. RNAi knockdown was performed according to ref. 64 with minor
modifications. Relevant RNAi clones were sequenced to verify clone
identity. To induce RNAi in liquid cultures, worms were incubated with
the RNAi expression bacteria of interest in the presence of 1 mM IPTG and
25 μg/mL carbenicillin.
Microscopy. Light microscopy. Larvae and adults were anesthetized with 10mM
levamisole, mounted on 2% (vol/vol) agar slides, and stored in a humid box
until use. Images were captured using a Zeiss AxioImager M1 microscope
and Axiovision software. Images for intensity comparison were taken with
the same imaging parameters.
Confocal and superresolution microscopy. Embryos were harvested from gravid
adults andmounted on a 2% (vol/vol) agar pad, covered with a 50 μLM9 drop
and a small coverslip. Larvae and adults were immobilized on slides by using
either levamisole anesthetics or the dry agar slide technique described in
ref. 65. Images were captured using a Ziess LSM 510 confocal microscope. For
superresolution analysis, worms were immobilized on dry agar slides and
visualized using a Leica TCS sp5 II superresolution microscope (stimulated
emission depletion). After acquisition, images were deconvoluted using the
built-in deconvolution algorithms in the Leica LAS-AF software. The point
spread function was generated with a 2D Lorentz function with the dull-
width half-maximum set to 150 nm (as calculated on the image using the signal
energy algorithm; regularization parameter of 0.1). For each stage or condition,
n (number of animals) ≥ 15.












Oil-O-Red staining and measurement of total fat. The Oil-O-Red (Sigma; O9755)
staining method was followed (66) with minor modifications.
TMRE staining. TMRE powder (Molecular Probes; T669) was dissolved in DMSO
tomake a 1-mM stock solution. This stock was further diluted 100× in M9 and
used to stain worms for 30 min in microcentrifuge tubes in the dark. Then,
worms were washed two to three times in M9 and mounted on dry agar
slides. Because TMRE signal bleaches quickly samples were visualized using
confocal microscopy.
Oxygen consumption measurements. The oxygen consumption rate was mea-
sured in a Seahorse Biosciences Extracellular Flux Analyzer (model XF96)
using a protocol adapted from ref. 67. One-day-old worms of the indicated
genotype were washed in M9 medium (to remove bacteria) and placed on
bacteria-free nematode growth medium (NGM) agar plates. Ten worms
were then manually transferred to each well in an XF96 measurement plate
loaded with M9. Worms were allowed to settle to the bottom of the well,
and oxygen consumption was measured four times per well. At least three
different wells were measured for each condition or treatment.
Pharyngeal pumping and swimming measurements. To measure pharyngeal
pumping, plates of worms were placed in a high-magnification stereomi-
croscope. Pharyngeal pumping was captured in 1-min movies of individual
worms at 30 frames per s. These movies were opened in Image J and played
at 8 frames per s. Pharyngeal pumping in 450 frames (15 s) was counted
manually. To measure worm swimming, a single worm was placed in a drop
of 40 μL M9 on an NGM plate using an eyelash hair. After 10 min, the
swimming worm was captured in a movie as above. Analysis was done as
above but the number of body turns was counted in 30 s. A standard
body turn was defined as the complete change in direction of the
bending at the midbody.
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